TOLUWALASE TOFADE: Open Payments
NPI 1669968798 · LEONARDTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$237 in 11 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $20 · 2025 $237
Food & beverage: $237
| Company | Payments | Amount |
|---|---|---|
| Biogen, Inc. | 2 | $42 |
| Novartis Pharmaceuticals Corporation | 2 | $36 |
| GENZYME CORPORATION | 1 | $34 |
| ABBVIE INC. | 1 | $25 |
| Philips North America LLC | 1 | $24 |
| Lundbeck LLC | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Celgene Corporation | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
Products named: KESIMPTA, QULIPTA, ECC Solutions, TYSABRI, VYEPTI, DUPIXENT, ZEPOSIA, VUMERITY.
Industry payments across MD — which companies pay providers there.
